Reprogram Biosciences, a preclinical oncology biotechnology company developing mRNA-based therapeutics to treat solid tumors, today announced the close of its seed financing. The close brings total ...

Leuven, 11 March 2025 – Solid tumors often provide a challenging environment for the T cells of our immune system. By reprogramming the metabolism of T cells, scientists at the VIB-KU Leuven Center ...

Researchers at Oregon Health & Science University have uncovered a key reason why immunotherapy has largely failed in pancreatic cancer—and identified a promising strategy to overcome that resistance.

Solid tumors often provide a challenging environment for the T cells of our immune system. By reprogramming the metabolism of T cells, scientists at the VIB-KU Leuven Center for Cancer Biology and ...

Researchers from VIB, VUB, and an international network of collaborators have created the most comprehensive single-cell ...

NewLimit Series C raises $435M led by Founders Fund as Armstrong-backed startup moves epigenetic therapies toward human ...

A team has identified an experimental molecule capable of "reprogramming" the brain's immune cells to restore part of their ...

A team led by researchers has discovered that a group of cells located in the skin and other areas of the body, called neural crest stem cells, are the source of reprogrammed neurons found by other ...

NewLimit, which plans to take its young-again cell reprogramming therapy into the clinic next year, raised a $435 million ...

Cancer immunotherapy has advanced the field of medicine and cancer care. Specifically, immunotherapy refers to the targeted treatment of the immune system. Over the last few decades, immunotherapy has ...